SB 201146 Usage And Synthesis

Description

SB 201146 is a leukotriene B4 antagonist. SB 201146 is a trisubstituted pyridine with high affinity for the LTB4 receptor.

Uses

SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma[1].

References

[1] Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals